التفاصيل البيبلوغرافية
| العنوان: |
Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report. |
| المؤلفون: |
Boukansa, Sara, Mouhrach, Ismail, El Agy, Fatima, El Bardai, Sanae, Bouguenouch, Laila, Serraj, Mounia, Amara, Bouchra, Ouadnouni, Yassine, Smahi, Mohamed, Alami, Badreeddine, Mellas, Nawfel, Benbrahim, Zineb, El Fatemi, Hinde |
| المصدر: |
PLoS ONE; 6/5/2024, Vol. 19 Issue 6, p1-17, 17p |
| مصطلحات موضوعية: |
NON-small-cell lung carcinoma, EPIDERMAL growth factor receptors, PROGNOSIS, CANCER patients, PROTEIN-tyrosine kinase inhibitors |
| مستخلص: |
Background: Non-small cell lung cancer (NSCLC) remains a significant global health concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This prospective study investigated the prevalence and clinical implications of EGFR mutations in Moroccan NSCLC patients. Methods: A cohort of 302 NSCLC patients was analyzed for EGFR mutations using multiple techniques. Demographic, clinical, and pathological characteristics were assessed, and overall survival (OS) outcomes were compared among different EGFR mutation subtypes. Results: EGFR mutations were present in 23.5% of patients, with common mutations (81.69%) dominating. Common mutations showed strong associations with female gender and non-smoking status, while rare mutations were associated with a positive smoking history. Patients with EGFR mutations receiving tyrosine kinase inhibitors (TKIs) had significantly improved OS compared to wild-type EGFR patients. Notably, patients with common EGFR mutations had the highest OS, while those with rare mutations had a shorter survival period, albeit not statistically significant. Conclusion: This study highlights the relevance of EGFR mutation status in NSCLC patients, particularly in therapeutic decision-making. The association between smoking history and rare mutations suggests the need for tailored approaches. The survival advantage for patients with common EGFR mutations underscores the significance of personalized treatment strategies. [ABSTRACT FROM AUTHOR] |
|
Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder